Company
Vibalogics is a partner for companies committed to developing therapeutic and prophylactic vaccines and biologics. Our company is a one-stop-shop for virus manufacturing, bacterial manufacturing, quality control, formulating, filling, and lyophilization. Whenever required we work in full compliance with international GMP standards in a BSL2-classified state-of-the-art facility.

 

Products produced by Vibalogics are predominantly used for prophylactic vaccination, therapeutic vaccination, gene therapy or virotherapy using oncolytic viruses.

 

 

 

Vibalogics places the greatest value on being a reliable partner and offering high-quality services. Our company distinguishes itself by being highly flexible, establishing and maintaining open communication lines and making our partners' aims our own.

 

Vibalogics takes pleasure in inviting you to study the following pages for additional information. Feel free to contact our team directly who will be happy to assist you.

 

Feasibility study using CAP® Technology and a model viral vector yields meaningful data.


CEVEC Pharmaceuticals, the developer of CAP® cell Technology, a novel human expression system derived from amniocytes and Vibalogics GmbH, international manufacturer of viruses and bacteria for novel biological products have recently collaborated ... read more


Schedule of Events:  

- BIO Europe 2012 International Partnering Conference, Hamburg, Germany,  November 12 - 14, 2012

- ACTIP-Meeting, Marburg, Germany, December 13 - 14, 2012, Presentation by Kai Lipinski

- World Vaccine Manufacturing Congress, Washington D.C., United States, April 16 - 18, 2013

- BIO International Convention, Chicago, USA, April 22 - 25, 2013

- Vaccine Emerging Markets, Berlin, Germany, June 10 - 11, 2013

- World Vaccine Congress Asia, Singapore, June 17 - 20, 2013

- World Vaccine Congress, Lille, France, October 16 - 17, 2013